A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma Clinical Trial

Official title:

A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03688152
• Other study ID #: INCB 53914-102
• Status: Completed
• Phase: Phase 1
• Start date: December 3, 2018
• Est. completion date: September 1, 2020

Study information

• Verified date: November 2020
• Source: Incyte Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: September 1, 2020
• Est. primary completion date: September 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Relapsed or refractory DLBCL, which has been histologically documented, defined as having received at least 2 but no more than 5 prior systemic treatment regimens (eg, an anti-CD20 antibody, an anti-CD20 antibody with or without chemotherapy, or chemotherapy alone) and ineligible for further treatment with standard of care.

• Willing to undergo pretreatment and on-treatment incisional or excisional biopsy of nontarget adenopathy or extranodal lesions. Provision of the most recent, available archived tumor biopsy may satisfy the pretreatment biopsy.

• Measurable disease as defined by the Lugano classification criteria:

• = 1 measurable nodal lesion (= 1.5 cm in longest dimension) or = 1 measurable extranodal lesion (> 1 cm in longest dimension) on CT scan or MRI

• = 1 PET-avid lesion.

• Eastern Cooperative Oncology Group performance status 0 to 2.

• Willingness to avoid pregnancy or fathering children based on protocol-defined the criteria.

Exclusion Criteria:

• Laboratory values outside the protocol-defined range at screening unless approved by the medical monitor.

• Primary mediastinal (thymic) large B-cell lymphoma or Richter's Syndrome.

• Known brain or central nervous system metastases or history of uncontrolled seizures.

• Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.

• Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.

• Use of immunosuppressive therapy following allogenic transplant within 28 days of the first dose of study treatment.

• Prior treatment with a PIM inhibitor, selective PI3Kd inhibitor (eg, idelalisib), or a pan-PI3K inhibitor.

• Receipt of anticancer medications, therapies, or investigational drugs within protocol-defined intervals before the date of the first dose of study treatment.

• Current or previous other malignancy within 3 years of study entry, except cured (or treated with curative intent and no evidence of disease) basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.

• History of liver function abnormality requiring investigation and/or treatment (eg, due to excessive alcohol or drug-induced liver injury).

• Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.

• Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment, and exposure to a live vaccine within 30 days of study treatment administration.

• Known HIV infection.

• Evidence of HBV or HCV infection.

• History of stroke or intracranial hemorrhage within 6 months of the date of study treatment administration.

• History of clinically significant or uncontrolled cardiac disease.

• Presence of an abnormal ECG that is clinically meaningful. Screening QTc interval > 480 milliseconds is excluded (corrected by Fridericia).

• Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Refractory Diffuse Large B-Cell Lymphoma
• Relapsed Diffuse Large B-Cell Lymphoma

Intervention

Drug:
• INCB053914
Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria. Dose Expansion: Recommended dose from the dose-escalation study.
• INCB050465
Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria. Dose Expansion: Recommended dose from the dose-escalation study.

Locations

Country	Name	City	State
United States	Clinical Research Alliance	Lake Success	New York
United States	UCLA Healthcare Hematology-Oncology	Santa Monica	California
United States	University of Arizona Cancer Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of treatment-emergent adverse events (TEAEs)	TEAE is defined as an adverse event reported for the first time or worsening of a pre-existing event after the first dose of study treatment.	Up to approximately 6 months
Secondary	Cmax of INCB053914 in combination with INCB050465	Maximum observed plasma concentration.	Day 15
Secondary	Tmax of INCB053914 in combination with INCB050465	Time to maximum plasma concentration.	Day 15
Secondary	Cmin of INCB053914 in combination with INCB050465	Minimum observed plasma concentration during the dosing interval.	Day 15
Secondary	AUC0-t of INCB053914 in combination with INCB050465	Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration.	Day 15
Secondary	Cl/F of INCB053914 in combination with INCB050465	Oral dose clearance.	Day 15
Secondary	Overall response rate	Defined as the percentage of participants with a complete remission (CR)/complete metabolic response (CMR) or partial remission (PR)/partial metabolic response (PMR) as defined by investigator assessment per revised Lugano classification criteria for lymphomas.	Up to approximately 6 months
Secondary	Duration of response	Defined as the time from first documented evidence of CR/CMR or PR/PMR until disease progression or death from any cause among participants who achieve an objective response, as determined by radiographic disease assessment.	Up to approximately 6 months
Secondary	Progression-free survival	Defined as the time from the date of the first dose of any study drug until the earliest date of disease progression, as determined by radiographic disease assessment, or death from any cause, whichever occurs first.	Up to approximately 6 months